Загрузка...
RRx-001 Acts as a Dual Small Molecule Checkpoint Inhibitor by Downregulating CD47 on Cancer Cells and SIRP-α on Monocytes/Macrophages
RRx-001 is a pleiotropic anticancer agent in phase III clinical trials, which polarizes tumor-associated macrophages from a low phagocytic M2 phenotype to a high phagocytic M1 phenotype. One of the ways in which tumors promote M2 polarization and evade macrophage-mediated destruction is through upre...
Сохранить в:
| Опубликовано в: : | Transl Oncol |
|---|---|
| Главный автор: | |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Neoplasia Press
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6370857/ https://ncbi.nlm.nih.gov/pubmed/30738349 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2018.12.001 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|